Reliable, high throughput KV7 assays are important because KV7 ion channels play a key role in regulating neuronal excitability, which is closely linked to both pain signalling and seizure activity.
KV7 ion channels are highly relevant to epilepsy because they are voltage gated potassium ion channels that help regulate neuronal excitability and suppress excessive electrical firing in the brain. By allowing potassium ions to leave neurons during electrical activity, KV7 channels help stabilise membrane potential and reduce the likelihood of uncontrolled firing.
When KV7 ion channel activity is reduced, neurons may become hyperexcitable, increasing the risk of abnormal synchronised activity that can lead to seizures. Genetic variants in KCNQ2 and KCNQ3, which encode KV7.2 and KV7.3 channel subunits, have been associated with several forms of epilepsy, including benign familial neonatal epilepsy and severe developmental and epileptic encephalopathies. These findings have established KV7 channels as clinically important ion channel targets in epilepsy research.
From a pharmacological perspective, KV7 channel openers can enhance potassium conductance and help restore normal neuronal firing patterns. Retigabine, for example, was an anti epileptic drug that acted by enhancing Kv7 channel activity, demonstrating the therapeutic potential of this mechanism. Although retigabine is no longer widely used clinically, KV7 modulation remains an active area of ion channel drug discovery research.
Reliable, high throughput KV7 assays are important because KV7 ion channels play a key role in regulating neuronal excitability, which is closely linked to both pain signalling and seizure activity.
Kv7 channels are a family of voltage gated potassium ion channels that play a key role in controlling cellular excitability.